Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus Medtech (Hangzhou)'s quarterly market cap
increased
from Dec. 2024 ($4.76 Mil) to Jun. 2025 ($110.78 Mil) and
increased
from Jun. 2025 ($110.78 Mil) to Dec. 2025 ($118.24 Mil).
Venus Medtech (Hangzhou)'s annual market cap
declined
from Dec. 2023 ($283.39 Mil) to Dec. 2024 ($4.76 Mil) but then
increased
from Dec. 2024 ($4.76 Mil) to Dec. 2025 ($118.24 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Venus Medtech (Hangzhou)'s Enterprise Value for Today is $33.74 Mil.
Venus Medtech (Hangzhou) (OTCPK:VMTHF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Venus Medtech (Hangzhou) Market Cap Related Terms
Venus Medtech (Hangzhou) Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Market Cap distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Venus Medtech (Hangzhou)'s Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) (VMTHF) has a Market Cap of $63.54 Mil as of Aug. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Venus Medtech (Hangzhou) and its competitors. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #502 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 58.2%.
Is Venus Medtech (Hangzhou)'s Market Cap too high?
Venus Medtech (Hangzhou)'s current Market Cap is $63.54 Mil. The Medical Devices & Instruments industry median Market Cap is 112.48. Venus Medtech (Hangzhou)'s value of $63.54 Mil is 43.5% below this industry median. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #502 out of 863 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #502 out of 863 companies for Market Cap. This places Venus Medtech (Hangzhou) in the lower half of its industry. The industry median Market Cap is 112.48. Venus Medtech (Hangzhou)'s value of $63.54 Mil is 43.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 112.48, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Medtech (Hangzhou)'s current Market Cap of $63.54 Mil is 43.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 112.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current Market Cap is $63.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current Market Cap of $63.54 Mil. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current Market Cap is $63.54 Mil and 43.5% below the Medical Devices & Instruments industry median of 112.48. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current Market Cap is $63.54 Mil as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.
Key valuation signals for VMTHF:
Market Cap: $63.54 Mil
GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
Industry Position: 43.5% below the Medical Devices & Instruments median (#502 of 863)
No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for VMTHF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMTHF has been successfully added to your 
